RLX-33

• CAT Number: I043322
• CAS Number: 2784577-71-3
• Molecular Formula: C24H19ClN4O4
• Molecular Weight: 462.89
• Purity: ≥95%
• Synonyms: N-[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]-1-(furan-2-ylmethyl)-5-oxopyrrolidine-3-carboxamide
• InChI: InChI=1S/C24H19ClN4O4/c25-18-7-3-15(4-8-18)22-27-24(33-28-22)16-5-9-19(10-6-16)26-23(31)17-12-21(30)29(13-17)14-20-2-1-11-32-20/h1-11,17H,12-14H2,(H,26,31)
• InChIKey: LTOAWFRZXVPHAJ-UHFFFAOYSA-N
• SMILES: C1C(CN(C1=O)CC2=CC=CO2)C(=O)NC3=CC=C(C=C3)C4=NC(=NO4)C5=CC=C(C=C5)Cl

RLX-33（Cat No.:I043322）is a selective small molecule inhibitor of the protein kinase Akt, which plays a crucial role in regulating cell survival, growth, and metabolism. Akt is often dysregulated in cancers, leading to tumor growth, resistance to therapy, and metastasis. By inhibiting Akt, RLX-33 aims to block these oncogenic pathways, reduce tumor progression, and potentially enhance the effectiveness of existing cancer therapies. RLX-33 is being investigated for its potential to treat various cancers, particularly those driven by Akt activation, offering a targeted therapeutic approach to disrupt tumor cell survival and proliferation.